WHAT IS CLAIMED IS:

1. A method for treating a disorder with secretin, the method comprising the step of administering to an individual having the disorder an effective amount of secretin based on the individual's chymotrypsin level to improve a symptom of the disorder.

2. The method of claim 1, comprising the steps of:

obtaining a sample of feces from the individual;

measuring a quantitative level of chymotrypsin present in the sample; and

comparing the measured quantitative level with at least one threshold chymotrypsin level to determine the efficacy of secretin administration to the individual.

3. The method of claim 2, wherein the at least one threshold chymotrypsin level is based on a level of chymotrypsin associated with at least one other individual of the same approximate age that does not have the disorder.

4. The method of claim 2, wherein the at least one threshold chymotrypsin level is approximately 8.4 U/gm.

5. The method of claim 2, wherein the at least one threshold chymotrypsin level is approximately 4.2 U/gm.

6. The method of claim 1, wherein the disorder comprises a disorder within a PDD (pervasive developmental disorder) spectrum.

7. The method of claim 1, wherein the disorder comprises autism.

8. A method for treating a disorder with digestive enzymes, the method comprising the step of administering to an individual having the disorder an effective amount of digestive enzymes based on the individual's chymotrypsin level to improve a symptom of the disorder.

9. The method of claim 8, comprising the steps of:

obtaining a sample of feces from the individual;

measuring a quantitative level of chymotrypsin present in the sample; and

comparing the measured quantitative level with at least one threshold chymotrypsin level to determine the efficacy of secretin administration to the individual.

10. The method of claim 9, wherein the at least one threshold chymotrypsin level is based on a level of chymotrypsin associated with at least one other individual of the same approximate age that does not have the disorder.

11. The method of claim 9, wherein the at least one threshold chymotrypsin level is approximately 8.4 U/gm.

12. The method of claim 9, wherein the at least one threshold chymotrypsin level is approximately 4.2 U/gm.

13. The method of claim 8, wherein the disorder comprises a disorder within a PDD (pervasive developmental disorder) spectrum.

14. The method of claim 8, wherein the disorder comprises autism.

15. The method of claim 8, wherein the disorder comprises one of ADD (Attention Deficit Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) and both.

16. The method of claim 8, wherein the digestive enzymes comprise a pancreatic enzyme.

17. A method for treating an individual exhibiting a symptom of a PDD (pervasive developmental disorder), the method comprising administering to the individual an effective amount of digestive enzymes to improve one or more symptoms of the disorder.

18. The method of claim 17, wherein the disorder comprises autism.

19. The method of claim 17, wherein the disorder comprises ADD (Attention Deficit Disorder), ADHD (Attention Deficit Hyperactivity Disorder) and both.

20. The method of claim 17, wherein the digestive enzymes comprise a pancreatic enzyme.

21. The method of claim 17, wherein the step of administering digestive enzymes comprises administering a quantitative level of digestive enzymes on a daily basis based at least on the age of the individual.

22. The method of claim 21, wherein the digestive enzymes are administered three times per day.